$QGEN News

QIAGEN N.V. Enters Business Combination Agreement for Planned Tender Offer by Crown NL Bidco B.V. at €46.50 Per Share

Long-Awaited Qiagen Buyout Closes At 15x EBITDA Multiple as Slow Growth Curbs Pricing

This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

JP Morgan Downgrades Qiagen to Neutral, Lowers Price Target to $52

Baird Maintains Outperform on Qiagen, Raises Price Target to $52

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

QIAGEN reports preliminary Q3 2026 results

QIAGEN Reports Preliminary Q3 Net Sales Of $548M; Preliminary Q3 Adj EPS $0.65; Co. Suspends FY 2026 Outlook While Transaction With EQT Private Equity Is Pending

Qiagen And EQT Private Equity Agree On An All-Cash Public Takeover Offer For All Outstanding Qiagen Shares At An Offer Price Of €46.50 Per Share, A Premium Of 40.3% To The Unaffected Share Price; Closing Expected In Mid-2027

Qiagen (QGEN) Stock Looks Like A Bargain On Cash Flow

'EQT Is in Advanced Talks to Buy Testing Firm Qiagen' - Bloomberg

QIAGEN N.V. (NYSE:QGEN) Sets Up for a Technical Breakout

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

Barclays Upgrades Qiagen N.V. to Overweight from Equal-Weight

Barclays Upgrades Qiagen to Overweight, Raises Price Target to $55

Qiagen (QGEN), What Is Behind The Fresh Attention Now?

What Qiagen (QGEN)'s Expanded Sepsis Testing Portfolio Means For Shareholders

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker